The Mammography Flap: The Impact of New Guidelines on Comparative Effectiveness Research
This article was originally published in RPM Report
Executive Summary
Recommendations from a government-appointed panel that would raise the age at which women should be screened for breast cancer created a great public uproar. There's little doubt the messaging campaign was a PR disaster. But the new guidelines may have more profound implications on comparative effectiveness research.
You may also be interested in...
The Value Proposition: Why Pharma Should Embrace Comparative Effectiveness
A greater investment in comparative effectiveness research appears inevitable, whether or not Congress creates a federally funded agency to conduct head-to-head trials. The Vytorin debacle is only the most recent reason why industry is wary. But there are steps pharma can take to prepare for the next big thing in health care policy. Despite Vytorin, Merck is one of the companies leading the way.
Aranesp Awaits Label Transplant As Committee Mulls Alternate Trial Designs
Amgen avoided an immediate setback when a Cardiovascular and Renal Drugs Advisory Committee meeting on Oct. 18 voted against further restrictions on the use of Aranesp (darbepoetin alfa) in chronic kidney disease (CKD) patients.
"Value-Based" Insurance Designs Can Give Unexpected Boost To Brands
Health care plans that adopt innovative “value-based” insurance designs to control costs are providing an unexpected sales boost for some brand-name drug manufacturers and vaccine makers.